LEO 22811 - A Phase 1, Double-Blind, Placebo-controlled, Single and Multiple Oral Dose Study in Healthy Subjects

• Status: Completed
• Trial end date: 2009-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this first-in-man trial is to determine the safety and tolerability of ascending single and multiple doses of LEO 22811 in healthy male subjects as well as to determine the safety and tolerability of single oral doses of LEO 22811 in healthy female subjects. The trial will be performed in two parts. In Part 1, single doses of LEO 22811 will be administered to healthy male and female subjects. In Part 2, multiple doses of LEO 22811 will be administered to healthy male subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: LEO Pharma
• Treatments: Pharmaceutical Solutions

Criteria

Inclusion Criteria: (in summary)

• Subjects will be Caucasian males or females of non-child bearing potential between 18 and 65 years of age

• Subjects will have given their written informed consent to participate in the study and to abide by the study restrictions

Exclusion Criteria: (in summary)

• Women of childbearing potential

• Subjects with an infectious illness within 3 days prior to dosing

• Subjects with a history of tuberculosis

• Subjects who have received any prescribed systemic or topical medication (including natural/herbal medicines) within 14 days of the first dose administration

• Subjects who have used any non-prescribed systemic or topical medication (including herbal remedies) within 7 days of the first dose administration

• In Part 2, subjects who have received or been exposed to Cloroquine products, endoxan, or any immunomodulating agent (e.g. azathioprin) within one month prior to the start of dosing

• Subjects who are participating in a clinical study

• Subjects with a significant history of drug allergy or with a known or suspected hypersensitivity to any of the components of LEO 22811 as determined by the Investigator

• Subjects who have any clinically significant allergic disease (excluding non-active hayfever) as determined by the Investigator

• Subjects who have a supine blood pressure and supine pulse rate at screening higher than 150/90 mmHg and 100 beats per minute (bpm), respectively, or lower than 90/40 mmHg and 50 bpm, respectively

• Subjects who have PR interval >= 200 ms, QTc(b) interval >450 ms (males) or > 470 ms (females), or who exhibit U waves of atrio-ventricular blocks at screening, based on 12-lead ECGs

• Subjects who consume more than 28 units (males) or more than 21 units (females) of alcohol per week or who have a significant history of alcoholism or drug/chemical abuse

• Subjects who smoke more than 5 cigarettes or the equivalent in tobacco per day

• Subjects with a significant cardiac history (e.g. heart failure, hypokalemia, long QT syndrome)

• Subjects who have had a clinically significant illness within 4 weeks of the start of dose administration as determined by the Investigator

• Subjects who, in the opinion of their General Practitioner (GP) or the Investigator, should not participate in the study, including subjects suspected for whatever reason of not being able to comply with the requirements of the protocol